Online first
Clinical vignette
Published online: 2024-06-21
Complications of immunotherapy in the course of long-term response in a patient with non-small cell lung cancer
12
, 12, 23
, 12, 23
Abstract
Not available
Keywords: pembrolizumablung adenocarcinomaimmunotherapy
References
- Mok TSK, Wu YL, Kudaba I, et al. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183): 1819–1830.
- Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019; 290(1): 6–23.
- Cybulska-Stopa B, Czarnecka AM, Kamińska-Winciorek G, Rutkowski P. Bezpieczeństwo immunoterapii: zasady postępowania profilaktyczno-terapeutycznego w przypadku wystąpienia działań niepożądanych. Wyd. 2. Via Medica, Gdańsk 2022.
- Liu H, Li Y, Li J, et al. Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol. 2023; 14: 1199031.